Literature DB >> 22346393

Reasons for choice of antibiotic for the empirical treatment of CAP by Canadian infectious disease physicians.

J Pendergrast1, T Marrie.   

Abstract

BACKGROUND: Previous studies have documented substantial variation in physician prescribing practices for the treatment of community-acquired pneumonia. Much of this variation is the result of empirical treatment, in which physicians must choose antibiotics in the a8bsence of culture and sensitivity data.
OBJECTIVE: To explore the factors that influence antibiotic choice for the empirical treatment of community-acquired pneumonia.
MATERIALS AND METHODS: Case-based questionnaires were mailed to all 157 members of the Canadian Infectious Disease Society in June 1996. The questionnaires presented three clinical cases and asked respondents which antibiotics they would most likely prescribe. Half the questionnaires were closed-ended, and half were open-ended. In the former, respondents were asked to explain their antibiotic choice by assigning weights to a list of clinical factors. In the latter, respondents were asked to explain their antibiotic choice by providing a short written answer. Respondents were grouped by the class of antibiotics they selected. These groups were then compared with regards to respondent characteristics (age, years of infectious disease experience, adult versus pediatric practice, country of training, province of practice) and rationale for the treatment chosen. Rationale for drug choice was analyzed statistically for the closed-ended questionnaires and qualitatively for the open-ended questionnaires.
RESULTS: A response rate of 84.6% was obtained. For the first clinical case, in which the patient was young and had no underlying illness, the majority of respondents chose a macrolide (74.7%). In the second case, in which the patient was older and had evidence of comorbidity, the most common choice of antibiotic was a penicillin (40.8%). In the third case, in which the patient had intensive care unit-requiring pneumonia, the most popular choice was combination therapy of a third-generation cephalosporin and a macrolide (43.2%). There was decreasing consensus regarding the choice of antibiotics as the complexity of the cases increased. There was evidence that prescribing variation could occasionally be attributed to both respondent characteristics and the use of different decision-making strategies.
CONCLUSIONS: Despite the relative homogeneity of the physicians studied, considerable variation in antibiotic choice was observed. In the first case, this variation was based on the issue of whether the patient had a typical or atypical infection. In the second case, the choice of antibiotic was related to the issue of infection by Haemophilus influenzae, although the results of the Gram stain suggested a pneumococcal infection. In the third case, variance appeared to be based more on the respondent's age and province of practice than on any difference in decision-making strategy.

Entities:  

Keywords:  Amtibiotic choice; Decision-making; Pneumonia; Treatment

Year:  1999        PMID: 22346393      PMCID: PMC3250708          DOI: 10.1155/1999/928438

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  29 in total

1.  Antibiotic usage in community-acquired pneumonia: results of a survey in 288 departments of internal medicine in German hospitals.

Authors:  I Kappstein; F D Daschner
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

Review 2.  Clinical practice. How physicians make medical decisions and why medical decision making can help.

Authors:  G R Bergus; R M Hamm
Journal:  Prim Care       Date:  1995-06       Impact factor: 2.907

3.  Guidelines for the management of community-acquired pneumonia in adults. Italian Society of Pneumology. Italian Society of Respiratory Medicine. Italian Society of Chemotherapy.

Authors:  G Gialdroni Grassi; L Bianchi
Journal:  Monaldi Arch Chest Dis       Date:  1995-01

4.  Rationales expressed by empiric antibiotic prescribers.

Authors:  C D Hepler; K E Clyne; S T Donta
Journal:  Am J Hosp Pharm       Date:  1982-10

5.  A clinical pharmacy-oriented drug surveillance network: results of a nationwide antibiotic utilization review of bacterial pneumonia--1987.

Authors:  T H Grasela; J J Schentag; S J Boekenoogen; K D Crist; W L Lowes; B L Lum
Journal:  DICP       Date:  1989-02

6.  How physicians choose drugs.

Authors:  P Denig; F M Haaijer-Ruskamp; D H Zijsling
Journal:  Soc Sci Med       Date:  1988       Impact factor: 4.634

7.  Antibiotic prescribing patterns in Italian hospital inpatients with pneumonia, chronic obstructive pulmonary disease, and urinary tract infections.

Authors:  L Guglielmo; R Leone; U Moretti; A Conforti; A Spolaor; G Velo
Journal:  Ann Pharmacother       Date:  1993-01       Impact factor: 3.154

Review 8.  Community-acquired pneumonia requiring hospitalisation. Factors of importance for the short-and long term prognosis.

Authors:  J Hedlund
Journal:  Scand J Infect Dis Suppl       Date:  1995

Review 9.  Pneumonia. Patient profiles, choice of empiric therapy, and the place of third-generation cephalosporins.

Authors:  J M Leedom
Journal:  Diagn Microbiol Infect Dis       Date:  1992-01       Impact factor: 2.803

Review 10.  Empirical therapy of community-acquired pneumonia.

Authors:  M S Niederman
Journal:  Semin Respir Infect       Date:  1994-09
View more
  1 in total

1.  How Nova Scotia general practitioners choose antibiotics for the empirical treatment of community-acquired pneumonia.

Authors:  J Pendergrast; T J Marrie
Journal:  Can J Infect Dis       Date:  2000-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.